Ieq Capital LLC Acquires 34,613 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Ieq Capital LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 825.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 38,806 shares of the biopharmaceutical company's stock after acquiring an additional 34,613 shares during the quarter. Ieq Capital LLC's holdings in Alnylam Pharmaceuticals were worth $9,131,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Venturi Wealth Management LLC lifted its holdings in Alnylam Pharmaceuticals by 6,200.0% in the 4th quarter. Venturi Wealth Management LLC now owns 252 shares of the biopharmaceutical company's stock worth $59,000 after purchasing an additional 248 shares during the last quarter. Truist Financial Corp lifted its stake in shares of Alnylam Pharmaceuticals by 136.6% in the fourth quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock worth $1,035,000 after buying an additional 2,539 shares during the last quarter. CIBC Asset Management Inc lifted its stake in shares of Alnylam Pharmaceuticals by 14.5% in the fourth quarter. CIBC Asset Management Inc now owns 5,134 shares of the biopharmaceutical company's stock worth $1,208,000 after buying an additional 651 shares during the last quarter. Sanctuary Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 7.8% during the 4th quarter. Sanctuary Advisors LLC now owns 4,915 shares of the biopharmaceutical company's stock worth $1,157,000 after buying an additional 357 shares during the period. Finally, Capital Performance Advisors LLP grew its stake in Alnylam Pharmaceuticals by 99.3% in the 4th quarter. Capital Performance Advisors LLP now owns 877 shares of the biopharmaceutical company's stock valued at $206,000 after buying an additional 437 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 5,219 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the transaction, the chief executive officer now directly owns 78,880 shares of the company's stock, valued at $19,797,302.40. The trade was a 6.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the company's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the transaction, the executive vice president now owns 14,321 shares in the company, valued at approximately $3,654,862.41. This trade represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 81,356 shares of company stock valued at $22,498,551. 1.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ALNY. William Blair reissued an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Piper Sandler reissued an "overweight" rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Sanford C. Bernstein decreased their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th. Barclays lifted their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an "overweight" rating in a research report on Friday, November 1st. Finally, Raymond James increased their price objective on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an "outperform" rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $299.48.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY traded down $0.41 during trading hours on Friday, reaching $250.59. The company had a trading volume of 653,580 shares, compared to its average volume of 693,794. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The stock has a 50-day moving average of $254.14 and a two-hundred day moving average of $263.02. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The firm has a market capitalization of $32.44 billion, a PE ratio of -115.48 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.